Risperidone versus other atypical antipsychotics for schizophrenia.
BACKGROUND
In many countries of the industrialised world second-generation ("atypical") antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this review we examined how the efficacy and tolerability of risperidone differs from that of other SGAs.


OBJECTIVE
To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.


METHODS
1. Electronic searching We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO.2. Reference searching We inspected the references of all identified studies for more trials.3. Personal contact We contacted the first author of each included study for missing information.4. Drug companies We contacted the manufacturers of all atypical antipsychotics included for additional data.


METHODS
We included all randomised, blinded trials comparing oral risperidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis.


METHODS
We extracted data independently. For dichotomous data we calculated risk ratio (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated mean differences (MD), again based on a random-effects model.


RESULTS
The review currently includes 45 blinded RCTs with 7760 participants. The number of RCTs available for each comparison varied: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, eleven with quetiapine, two with sertindole, three with ziprasidone and none with zotepine. Attrition from these studies was high (46.9%), leaving the interpretation of results problematic. Furthermore, 60% were industry sponsored, which can be a source of bias.There were few significant differences in overall acceptability of treatment as measured by leaving the studies early. Risperidone was slightly less acceptable than olanzapine, and slightly more acceptable than ziprasidone in this regard.Risperidone improved the general mental state (PANSS total score) slightly less than olanzapine (15 RCTs, n = 2390, MD 1.94 CI 0.58 to 3.31), but slightly more than quetiapine (9 RCTs, n = 1953, MD -3.09 CI -5.16 to -1.01) and ziprasidone (3 RCTs, n = 1016, MD -3.91 CI -7.55 to -0.27). The comparisons with the other SGA drugs were equivocal. Risperidone was also less efficacious than olanzapine and clozapine in terms of leaving the studies early due to inefficacy, but more efficacious than ziprasidone in the same outcome.Risperidone produced somewhat more extrapyramidal side effects than a number of other SGAs (use of antiparkinson medication versus clozapine 6 RCTs, n = 304, RR 2.57 CI 1.47 to 4.48, NNH 6 CI 33 to 3; versus olanzapine 13 RCTs, n = 2599, RR 1.28 CI 1.06 to 1.55, NNH 17 CI 9 to 100; versus quetiapine 6 RCTs, n = 1715, RR 1.98 CI 1.16 to 3.39, NNH 20 CI 10 to 100; versus ziprasidone 2 RCTs, n = 822, RR 1.42 CI 1.03 to 1.96, NNH not estimable; parkinsonism versus sertindole 1 RCT, n = 321, RR 4.11 CI 1.44 to 11.73, NNH 14 CI 100 to 8). Risperidone also increased prolactin levels clearly more than all comparators, except for amisulpride and sertindole for which no data were available.Other adverse events were less consistently reported, but risperidone may well produce more weight gain and/or associated metabolic problems than amisulpride (weight gain: 3 RCTs, n = 585, MD 0.99 CI 0.37 to 1.61), aripiprazole (cholesterol increase: 1 RCT, n = 83, MD 22.30 CI 4.91 to 39.69) and ziprasidone (cholesterol increase 2 RCTs, n = 767, MD 8.58 CI 1.11 to 16.04) but less than clozapine (weight gain 3 RCTs n = 373, MD -3.30 CI -5.65 to -0.95), olanzapine (weight gain 13 RCTs, n = 2116, MD -2.61 CI -3.74 to -1.48), quetiapine (cholesterol increase: 5 RCTs, n = 1433, MD -8.49 CI -12. 23 to -4.75) and sertindole (weight gain: 2 RCTs, n = 328, MD -0.99 CI -1.86 to -0.12). It may be less sedating than clozapine and quetiapine, lengthen the QTc interval less than sertindole (QTc change: 2 RCTs, n = 495, MD -18.60 CI -22.37 to 14.83), produce fewer seizures than clozapine (2 RCTs, n = 354, RR 0.22 CI 0.07 to 0.70, NNT 14 CI 8 to 33) and less sexual dysfunction in men than sertindole (2 RCTs, n = 437, RR 0.34 CI 0.16 to 0.76, NNT 13 CI 8 to 33).


CONCLUSIONS
Risperidone seems to produce somewhat more extrapyramidal side effects and clearly more prolactin increase than most other SGAs. It may also differ from other compounds in efficacy and in the occurrence of other adverse effects such as weight gain, metabolic problems, cardiac effects, sedation and seizures. Nevertheless, the large proportion of participants leaving studies early and incomplete reporting of outcomes makes it difficult to draw firm conclusions. Further large trials, especially comparing risperidone with those other new drugs for which only a few RCTs are available, are needed.
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Moehlstrasse 26, München, Germany, 81675.
Katja
K
Komossa
Christine
C
Rummel-Kluge
Sandra
S
Schwarz
Franziska
F
Schmid
Heike
H
Hunger
Werner
W
Kissling
Stefan
S
Leucht
D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000031:analogs & derivatives / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007093:Imidazoles; D007211:Indoles; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D013469:Sulpiride; D000077582:Amisulpride; D000068180:Aripiprazole; C066304:sertindole; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
J Clin Psychiatry. 2003 Nov;64(11):1342-8
14658949
J Gen Intern Med. 1992 Nov-Dec;7(6):623-9
1453246
Psychopharmacol Bull. 1989;25(2):222-6
2574895
JAMA. 2001 Apr 18;285(15):1987-91
11308435
Am J Psychiatry. 1994 Jun;151(6):825-35
7514366
J Clin Psychopharmacol. 2006 Jun;26(3):238-49
16702888
Eur Neuropsychopharmacol. 1996;6 Suppl 2:S21-5
8792117
Am J Psychiatry. 1996 Mar;153(3):417-9
8610833
J Formos Med Assoc. 2003 Jan;102(1):30-6
12684609
Therapie. 1999 Jul Aug;54(4):405-11
10667106
Wien Klin Wochenschr. 2003 Jan 31;115(1-2):58-62
12658913
Schizophr Res. 2006 Sep;86(1-3):234-43
16887334
Psychiatry Res. 1999 Nov 8;88(2):107-17
10622347
Aust N Z J Psychiatry. 2006 May;40(5):437-45
16683970
Schizophr Res. 2003 Jun 1;61(2-3):303-14
12729882
Acta Psychiatr Scand. 2004 Apr;109(4):269-74
15008800
Stat Med. 2002 Oct 15;21(19):2971-80
12325113
Schizophr Res. 2008 Jul;102(1-3):1-18
18514488
Int J Neuropsychopharmacol. 2003 Dec;6(4):403-8
14604455
Psychopharmacology (Berl). 2003 Sep;169(3-4):390-7
12827347
Pharmacol Res. 2003 Oct;48(4):411-4
12902213
J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):45S-51S
7537287
Am J Psychiatry. 2007 Jul;164(7):1050-60
17606657
Am J Psychiatry. 1998 Apr;155(4):499-504
9545995
Neuropsychopharmacology. 2004 Jan;29(1):133-45
14583740
BMC Psychiatry. 2006 Feb 21;6:8
16504026
Am J Psychiatry. 2002 Feb;159(2):255-62
11823268
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001359
15846619
Pharmacoeconomics. 2000 Dec;18(6):567-79
11227395
Psychopharmacology (Berl). 2005 Dec;183(3):383-6
16240162
Psychopharmacology (Berl). 2001 May;155(3):230-3
11432684
Schizophr Res. 2006 Jan 1;81(1):1-15
16202565
Br J Psychiatry. 2005 Oct;187:366-71
16199797
Clin Ther. 2000 Sep;22(9):1085-96
11048906
Schizophr Res. 2005 Oct 15;78(2-3):157-9
16102942
Am J Psychiatry. 1999 Nov;156(11):1744-50
10553738
Nervenarzt. 2000 May;71(5):329-44
10846708
J Clin Psychiatry. 2003 May;64(5):598-604
12755665
J Clin Endocrinol Metab. 2003 Dec;88(12):5875-80
14671184
J Clin Psychiatry. 2006 Dec;67(12):1912-9
17194269
Health Technol Assess. 1999;3(5):iii-92
10982317
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005237
16625629
BMJ. 1997 Sep 6;315(7108):600
9302962
Am J Psychiatry. 2009 Feb;166(2):152-63
19015230
Am J Psychiatry. 2003 Feb;160(2):290-6
12562575
Clin Ther. 2001 Nov;23(11):1839-54
11768836
Am J Psychiatry. 2006 Feb;163(2):185-94
16449469
Psychopharmacol Bull. 2006;39(1):105-16
17065975
J Clin Psychiatry. 2007 Jan;68(1):29-36
17284127
J Clin Psychiatry. 2006 Aug;67(8):1253-60
16965204
Neuropsychopharmacology. 2004 Mar;29(3):636; author reply 637-8
14973433
N Engl J Med. 1994 Mar 10;330(10):681-90
8107719
Am J Psychiatry. 2005 May;162(5):1013-6
15863811
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):659-65
15276691
Clin Neuropharmacol. 2005 Jul-Aug;28(4):163-8
16062094
Biol Psychiatry. 2005 Mar 15;57(6):577-85
15780844
J Clin Psychiatry. 2001 Mar;62(3):191-8
11305706
Schizophr Res. 1999 Dec 21;40(3):255-6
10638864
Arch Gen Psychiatry. 1978 Feb;35(2):153-5
623501
J Clin Psychopharmacol. 2005 Aug;25(4):381-6
16012284
J Clin Psychopharmacol. 2004 Feb;24(1):56-61
14709948
Am J Psychiatry. 2006 Apr;163(4):600-10
16585434
Cochrane Database Syst Rev. 2000;(3):CD002306
10908551
J Clin Psychopharmacol. 2005 Jun;25(3):278-81
15876912
J Clin Psychiatry. 2004 Jan;65(1):57-61
14744169
Acta Psychiatr Scand Suppl. 1970;212:11-9
4917967
J Clin Epidemiol. 2006 Jan;59(1):7-10
16360555
J Clin Psychiatry. 2006 Oct;67(10):1511-21
17107241
Ann Clin Psychiatry. 1994 Sep;6(3):173-80
7533585
Am J Psychiatry. 2006 Apr;163(4):611-22
16585435
Aust N Z J Psychiatry. 2000 Oct;34(5):801-8
11037366
Am J Psychiatry. 2001 Aug;158(8):1305-13
11481167
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jan;18(1):129-37
7509495
Am J Geriatr Psychiatry. 2003 Nov-Dec;11(6):638-47
14609804
Psychoneuroendocrinology. 2006 Apr;31(3):340-6
16198059
Int Clin Psychopharmacol. 2003 Nov;18(6):341-6
14571154
Psychiatry Res. 2004 Dec 15;129(2):159-69
15590043
Am J Psychiatry. 2004 Feb;161(2):364-7
14754789
Int Clin Psychopharmacol. 2002 Mar;17(2):65-8
11890188
Acta Psychiatr Scand. 2006 Feb;113(2):91-5
16423159
Am J Psychiatry. 2002 Jun;159(6):1018-28
12042192
J Clin Psychiatry. 2003 Sep;64(9):998-1004
14628974
Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):432-7
16267634
Schizophr Res. 2005 Nov 15;79(2-3):231-8
15982856
Int J Epidemiol. 2002 Feb;31(1):140-9
11914310
Br J Psychiatry. 1989 May;154:672-6
2574607
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Am J Psychiatry. 2006 Dec;163(12):2096-102
17151160
BMC Psychiatry. 2006 Oct 20;6:45
17054789
Int Clin Psychopharmacol. 2005 Jan;20(1):19-21
15602111
J Clin Psychiatry. 2005 Jan;66(1):80-4
15669892
Acta Psychiatr Scand Suppl. 1990;358:151-7
1978476
J Clin Psychiatry. 2001 Apr;62(4):231-8
11379836
BMJ. 1996 Nov 9;313(7066):1200
8916759
Am J Psychiatry. 1999 Feb;156(2):294-8
9989566
Arch Dis Child. 1999 Mar;80(3):210-1
10325697
Arch Gen Psychiatry. 2003 Jul;60(7):681-90
12860772
Psychol Med. 2000 Sep;30(5):1123-30
12027048
Neuropsychopharmacology. 2003 Aug;28(8):1491-500
12799617
Value Health. 2006 Mar-Apr;9(2):77-89
16626411
Schizophr Res. 2001 May 30;50(1-2):79-88
11378316
J Clin Psychiatry. 2004 Apr;65(4):551-6
15119920
Am J Geriatr Psychiatry. 2005 May;13(5):377-84
15879586
Br J Psychiatry. 2000 Mar;176:249-52
10755072
Mov Disord. 2000 Nov;15(6):1230-7
11104211
Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
15133589
Am J Psychiatry. 2004 Jun;161(6):975-84
15169685
Psychiatr Serv. 2004 Mar;55(3):290-4
15001730
N Engl J Med. 1997 Sep 18;337(12):809-15
9295240
Neuropsychopharmacology. 2002 Dec;27(6):1071-81
12464464
Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):911-22
11041534
Schizophr Res. 2006 May;84(1):77-89
16483745
J Clin Psychiatry. 2006 Jul;67(7):1093-103
16889453
Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
17015810
Am J Epidemiol. 1999 May 1;149(9):876-83
10221325
Schizophr Bull. 1984;10(3):388-98
6474101
Am J Psychiatry. 2001 May;158(5):765-74
11329400
Int J Psychiatry Clin Pract. 2006;10(2):138-41
24940964
J Clin Psychiatry. 2002 Feb;63(2):104-7
11874209
Psychopharmacology (Berl). 2006 Jul;186(4):572-8
16601995
Schizophr Res. 2006 Jul;85(1-3):254-65
16797162
Curr Med Res Opin. 2004 Sep;20(9):1483-91
15383198
Neuropsychopharmacology. 1998 Feb;18(2):63-101
9430133
Am J Psychiatry. 1992 Sep;149(9):1148-56
1386964
Schizophr Res. 2007 Sep;95(1-3):134-42
17662577
Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11
12590356
Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165
16707074
J Clin Psychopharmacol. 1997 Oct;17(5):407-18
9315992
J Clin Psychiatry. 2004 Dec;65(12):1624-33
15641867
Schizophr Res. 2002 Oct 1;57(2-3):311-3
12223264
J Clin Psychiatry. 2005 Aug;66(8):1021-30
16086618
J Clin Psychopharmacol. 2004 Apr;24(2):225-8
15206671
Psychiatr Serv. 2001 Nov;52(11):1510-4
11684748
Int Clin Psychopharmacol. 2006 Jan;21(1):49-56
16317317
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
3046553
Arch Gen Psychiatry. 2000 Mar;57(3):249-58
10711911
J Psychiatr Res. 2006 Oct;40(7):669-76
16762371
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004578
16625607
Psychopharmacology (Berl). 2002 Jun;162(1):3-10
12107610
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Drug Saf. 1995 Feb;12(2):139-45
7539272
J Clin Psychopharmacol. 2004 Feb;24(1):62-9
14709949